Results 21 to 30 of about 49,863 (275)

Omeprazole use and risk of chronic kidney disease evolution

PLoS ONE, 2020
Rationale, aims and objectives In recent years, the use of proton pump inhibitors (PPI), especially omeprazole, has been associated with development of chronic kidney disease (CKD). These drugs are widely used worldwide.
J. V. M. Guedes, J. A. Aquino, Tássia Lima Bernardino Castro, Flávio Augusto de Morais, A. Baldoni, V. S. Belo, Alba Otoni   +6 more
semanticscholar   +1 more source

Omeprazole Prevents Colistin-Induced Nephrotoxicity in Rats: Emphasis on Oxidative Stress, Inflammation, Apoptosis and Colistin Accumulation in Kidneys

Pharmaceuticals, 2022
The clinical value of colistin, a polymyxin antibiotic, is limited by its nephrotoxicity. Omeprazole is a commonly prescribed proton pump inhibitor.
Mohammed Z. Nasrullah, Khalid Eljaaly, Thikryat Neamatallah, Usama A. Fahmy, Abdulmohsin J. Alamoudi, Hussain T. Bakhsh, Ashraf B. Abdel-Naim   +6 more
doaj   +1 more source

A multicenter prospective study evaluating the impact of Proton Pump Inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.

British Journal of Clinical Pharmacology, 2020
Voriconazole is an antifungal metabolised by CYP2C19 enzyme, which can be inhibited by proton pump inhibitors (PPIs). A prospective observational study was carried out to determine the influence of PPIs on voriconazole pharmacokinetic.
S. Blanco Dorado, O. Maroñas, Ana Latorre-Pellicer, María Teresa Rodríguez Jato, Ana López-Vizcaíno, Áurea María Gómez Márquez, B. Bardán García, Dolores Belles Medall, G. Barbeito Castiñeiras, M. L. Pérez del Molino Bernal, M. Campos‐Toimil, F. O. Otero Espinar, Andrés Blanco Hortas, I. Zarra Ferro, Á. Carracedo, M. Lamas, A. Fernández-Ferreiro   +16 more
semanticscholar   +1 more source

Omeprazole-induced galactorrhea in kidney transplant patients—a case report

Journal of Medical Case Reports, 2022
Background Omeprazole belongs to the pharmacological classifications of proton pump inhibitors and is a widely used medicine. All proton pump inhibitors have a common mechanism of action and are prodrugs that require activation in an acidic environment ...
Choki Dorji, Farruk Ahammed Robin, Kesara Na-Bangchang   +2 more
doaj   +1 more source

Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction

Redox Biology, 2016
Proton pump inhibitors (PPIs) are widely used drugs that may increase the cardiovascular risk by mechanisms not entirely known. While PPIs increase asymmetric dimethylarginine (ADMA) levels and inhibit nitric oxide production, it is unknown whether ...
Lucas C. Pinheiro, Gustavo H. Oliveira-Paula, Rafael L. Portella, Danielle A. Guimarães, Celio D. de Angelis, Jose E. Tanus-Santos   +5 more
doaj   +1 more source

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis

Thorax, 2019
Background Cough is a common, disabling symptom of idiopathic pulmonary fibrosis (IPF), which may be exacerbated by acid reflux. Inhibiting gastric acid secretion could potentially reduce cough.
Prosenjit Dutta, W. Funston, H. Mossop, Vicky Ryan, Rhys T Jones, Rebecca Forbes, S. Sen, J. Pearson, S. M. Griffin, J. Smith, christopher Ward, Ian A. Forrest, John Simpson   +12 more
semanticscholar   +1 more source

Antioxidant protection enzyme activity in the blood serum and large intestinal mucosa of rats with prolonged gastric hypochlorhydria and given multiprobiotics

Regulatory Mechanisms in Biosystems, 2019
The activity of antioxidant protection enzymes in the blood serum and colon mucosa in rats was studied under the conditions of 28-days administration of omeprazole on its own and omeprazole together with multiprobiotics "Symbiter" and "Apibact ...
S. V. Pylypenko, A. A. Koval
doaj   +1 more source

Evaluation of the effects of medium‐term (57‐day) omeprazole administration and of omeprazole discontinuation on serum gastrin and serum chromogranin A concentrations in the horse

Journal of Veterinary Internal Medicine, 2023
Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) in horses after discontinuation of omeprazole.
Bethanie Clark, Catherine Steel, Jessica Vokes, Jack R. Shan, Kristene Gedye, Amy Lovett, B. W. Sykes   +6 more
doaj   +1 more source

Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. [PDF]

PLoS ONE, 2013
The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter.
Annamaria Tonazzi, Ivano Eberini, Cesare Indiveri   +2 more
doaj   +1 more source

A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide

Expert Opinion on Drug Metabolism & Toxicology, 2018
Background: Since the first oral glucagon-like peptide-1 analog comprises semaglutide co-formulated with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which induces a transient, localized increase in gastric pH, we have ...
T. Bækdal, Astrid Breitschaft, A. Navarria, C. W. Hansen   +3 more
semanticscholar   +1 more source